Zymeworks

Zymeworks doses first subject in Phase I trial of ZW191 for solid tumors
Clinical Trials Arena
Wed, 11/6/24 - 11:29 am
Zymeworks
clinical trials
ZW191
solid tumors
Zymeworks halts plans for phase 2 ADC trial to mull 'evolving clinical landscape'
Fierce Biotech
Thu, 03/7/24 - 11:37 am
antibody-drug conjugate
clinical trials
Zymeworks
zanidatamab
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Mon, 03/20/23 - 09:56 am
Zymeworks
Daiichi Sankyo
immuno-oncology
biobucks
Jazz hands Zymeworks a much-needed win for biliary tract cancer drug after peek at data
Fierce Biotech
Wed, 12/21/22 - 11:24 am
Zymeworks
Jazz Pharma
biliary tract cancer
zanidatamab
Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific
Fierce Biotech
Wed, 10/19/22 - 10:42 am
Jazz Pharmaceuticals
Zymeworks
HER2 inhbitor
bispecific antibodies
Zymeworks adds a classic poison pill defense to the armory as the biotech's board battles hostile takeover
Endpoints
Mon, 06/13/22 - 10:34 am
Zymeworks
M&A
poison pill
As its slide stretches into a second year, Zymeworks faces takeover bid
Endpoints
Fri, 04/29/22 - 10:43 am
Zymeworks
M&A
All Blue Falcons
Bloodletting at Zymeworks as new CEO axes half of senior leaders, plans 25% reduction in headcount
Fierce Biotech
Thu, 01/20/22 - 10:47 am
Zymeworks
layoffs
restructuring
ESMO Preview: Highlights to Watch for This Year
BioSpace
Wed, 09/15/21 - 10:29 pm
ESMO
oncology
cancer
Gilead Sciences
Bristol Myers Squibb
Zymeworks
Amgen
Adaptimmune Therapeutics
TCR2 Therapeutics
Boehringer Ingelheim
Zymeworks inks new antibody licensing deal with Merck
Pharma Letter
Thu, 07/9/20 - 10:54 am
Merck
Zymeworks
antibodies
drug discovery
4 Stocks Battling Breast Cancer
Motley Fool
Sat, 10/26/19 - 02:18 pm
Seattle Genetics
Macrogenics
Merus
Zymeworks
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks
Fierce Biotech
Thu, 04/25/19 - 11:45 am
Daiichi Sankyo
immuno-oncology
Zymeworks
bispecific antibodies
Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
Pharmaceutical Business Review
Mon, 01/21/19 - 10:49 am
Eli Lilly
Zymeworks
drug development
Azymetric platform
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics
Fierce Biotech
Tue, 11/27/18 - 11:32 pm
BeiGene
Zymeworks
bispecific antibodies
ZW25
ZW49
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
Endpoints
Mon, 11/13/17 - 09:16 am
JNJ
Zymeworks
drug development
bispecific antibodies
GSK doubles down on Zymeworks’ platform technologies with $908M deal
Fierce Biotech
Wed, 04/27/16 - 09:23 am
GSK
Zymeworks
R&D
bispecific antibodies
drug development
Zymeworks bags a $61.5M round, with a merger on tap and an IPO in view
Fierce Biotech
Fri, 01/8/16 - 11:42 am
Zymeworks
M&A
IPOs
Kairos Therapeutics
GlaxoSmithKline partners with fast-growing Zymeworks on antibody programs
Fierce Biotech
Thu, 12/3/15 - 09:32 am
GSK
Zymeworks
antibodies
R&D
Eli Lilly adds $375M to Zymeworks partnership
Yahoo/AP
Wed, 10/22/14 - 07:00 pm
Eli Lilly
Zymeworks
cancer immunotherapy

Pages